INT272221

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.11
First Reported 2007
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 3
Total Number 4
Disease Relevance 3.09
Pain Relevance 0.38

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (BRS3) signal transducer activity (BRS3)
BRS3 (Homo sapiens)
Pain Link Frequency Relevance Heat
long-term potentiation 78 77.48 Quite High
depression 72 76.84 Quite High
Transcranial magnetic stimulation 8 5.00 Very Low Very Low Very Low
medulla 4 5.00 Very Low Very Low Very Low
beta blocker 2 5.00 Very Low Very Low Very Low
c fibre 2 5.00 Very Low Very Low Very Low
Angina 2 5.00 Very Low Very Low Very Low
Pain 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Obesity 116 99.20 Very High Very High Very High
Myocardial Infarction 16 95.44 Very High Very High Very High
Thyroid Disease 4 95.28 Very High Very High Very High
Diabetes Mellitus 6 94.28 High High
Heart Disease 4 92.88 High High
Weight Loss 4 89.92 High High
Weight Gain 4 84.36 Quite High
Body Weight 2 82.00 Quite High
Depression 72 76.84 Quite High
Hyperinsulinism 4 32.16 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In our study, we found that HRT, which may be used instead of BRS, remains normal in obese subjects.
Gene_expression (used) of BRS associated with obesity
1) Confidence 0.11 Published 2007 Journal Journal of Korean Medical Science Section Body Doc Link PMC2693810 Disease Relevance 1.44 Pain Relevance 0
HRT is highly correlated with spontaneous BRS, and it may be used instead of BRS (24).
Gene_expression (used) of BRS
2) Confidence 0.11 Published 2007 Journal Journal of Korean Medical Science Section Body Doc Link PMC2693810 Disease Relevance 1.35 Pain Relevance 0
BTX treatment caused no significant changes in the BRS (baseline: 13±5.2 points; week 1: 13±4.0 points; week 2: 12.1±4.2 points; week 4: 10.7±4.6 points) or in the BDS (baseline: 67.7±27.2%; week 1: 64.6±25.2%; week 2: 63.8±26.3%; week 4: 71.9±15.7%) but a trend for a decrease in blink rate (F 3; 21?
Gene_expression (baseline) of BRS
3) Confidence 0.10 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2964285 Disease Relevance 0.15 Pain Relevance 0.19
BTX treatment caused no significant changes in the BRS (baseline: 13±5.2 points; week 1: 13±4.0 points; week 2: 12.1±4.2 points; week 4: 10.7±4.6 points) or in the BDS (baseline: 67.7±27.2%; week 1: 64.6±25.2%; week 2: 63.8±26.3%; week 4: 71.9±15.7%) but a trend for a decrease in blink rate (F 3; 21?
Neg (no) Gene_expression (changes) of BRS
4) Confidence 0.10 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2964285 Disease Relevance 0.15 Pain Relevance 0.19

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox